Fabrication, Design and In-vivo investigation of Mesoporous Silica Based Docetaxel Trihydrate Nanoparticles for Colonic Drug Delivery

Abstract

Background Mesoporous silica-loaded docetaxel trihydrate nanoparticles are the potential to target drug delivery toward a specific region with high stability and predictable release at the target region. They have large surface areas and mesoporous structures with large pore volumes, leading to high bioavailability and therapeutic efficacy at the disease site. This study demonstrates how nanoparticles can be prepared using an emulsion technique. Results The ratios of eudragit S100 to eudragit L100 polymers, along with phosphatidylcholine, were varied according to the response surface methodology. DSC and FTIR studies showed that mesoporous silica particles were successful. All formulations had average particle sizes ranging from 70.65 to 143.01nm, with a range of zeta potential from 17.6 ± 026 to 21 ± 011. In-vitro drug delivery studies were achieved for all formulations with a zeta potential of 17.6 ± 026 to 21 ± 011. After oral administration of the docetaxel, plasma levels were measured in vivo bioavailability testing of docetaxel. Docetaxel nanosuspension had a significantly higher Cmax amount than docetaxel micro-suspension (98.03 ± 23.40 ng/ml and 213.67 ± 72.21 ng/ml, respectively, with tmax 45 minutes). Docetaxel was more bioavailable in nanosuspension formulations, according to a bioavailability test of rats. Conclusion The results suggested that the mesoporous silica could be a great potential nanocarrier in colonic delivery with optimal drug content and controlled release docetaxel trihydrate.